Down-regulation of LAK cell-mediated cytotoxicity: cancer and ageing

This publication has 16 references indexed in Scilit:

• Defect in lectin-induced interleukin 2 production by peripheral blood lymphocytes of patients with invasive urinary bladder carcinoma
  Immunology Letters, 1988
• The regulatory effect of adherent cells on lymphokine activated killer cells
  Cellular Immunology, 1987
• Lymphokine-activated killer (LAK) cells: I. Age-dependent decline of LAK cell-mediated cytotoxicity
  Immunology Letters, 1987
• The effect of aging on the expression of interleukin 2 messenger ribonucleic acid
  Cellular Immunology, 1986
• Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
  New England Journal of Medicine, 1985
• Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
  The Journal of Immunology, 1985
• Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.
  The Journal of Experimental Medicine, 1983
• Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
  The Journal of Experimental Medicine, 1982
• Identification of T cell lymphoma tumor antigens on human T cell lines
  American Journal of Hematology, 1976
• Established cell line of urinary bladder carcinoma (T24) containing tumour‐specific antigen
  International Journal of Cancer, 1973